§
Luxuse
Patent Intelligence
Sign In
Patent US6323278B2 successfully refreshed from Google Patents.
← Back to Patent Explorer
US6323278B2 Expired / Lapsed US ⏱️ 0.0 years remaining

Method of making crosslinked polymer matrices in tissue treatment applications

Assignee: Angiodevice International GmbH
•
Filing: 2000-12-08
•
Granted: 2001-11-27
•
Expires: 2020-12-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH 2 ) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Inventors

  • 👤 Woonza M. Rhee
  • 👤 Frank A. Delustro
  • 👤 Richard A. Berg

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 12:22
CPC Classifications
A; A61; A61L; A61L31/00; A61L31/14; A61L31/16; A61L24/00; A61L24/04; A61L24/043; A61L24/08; A61L27/00; A61L27/14; A61L27/26; A61L27/28; A61L27/34; A61L27/50; A61L27/54; A61L31/04; A61L31/041; C; C08; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0075; C08G; C08G65/00; C08G65/02; C08G65/32; C08G65/329; C08H; C08H1/00; C08H1/06; C08L; C08L71/00; C08L71/02; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/232; A61L2300/252; A61L2300/60; A61L2300/606; Y; Y10; Y10S; Y10S623/00; Y10S623/90; Y10S623/901

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 108 words
A method for preparing a negatively charged compound-containing matrix useful for delivery of a negatively charged compound to a mammalian subject, comprising the steps of: providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups; forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking, wherein the first synthetic polymer is present in the mixture in molar excess compared to the second synthetic polymer; allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a positively charged crosslinked synthetic polymer matrix; and reacting the matrix with the negatively charged compound.
Claim 2
Independent Claim 108 words
A method for preparing a negatively charged compound-containing matrix useful for delivery of a negatively charged compound to a mammalian subject, comprising the steps of: providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups; forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking, wherein the first synthetic polymer is present in the mixture in molar excess compared to the second synthetic polymer; allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a positively charged crosslinked synthetic polymer matrix; and reacting the matrix with the negatively charged compound.
Claim 3
Dependent Claim 46 words
The method of claim 1 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
Claim 4
Dependent Claim 31 words
The method of claim 1 , wherein the first synthetic polymer is a polyethylene glycol, and wherein the nucleophilic groups are selected from a primary amino group and a thiol group.
Claim 5
Dependent Claim 24 words
The method of claim 1 , wherein the second synthetic polymer is a polyethylene glycol derivative, and wherein the electrophilic groups are succinimidyl groups.
Claim 6
Dependent Claim 14 words
The method of claim 1 , wherein the negatively charged compound is succinylated collagen.
Claim 7
Dependent Claim 50 words
The method of claim 1 , wherein the negatively charged compound is a negatively charged glycosaminoglycan derivative selected from the group consisting of: sodium hyaluronate, keratan sulfate, keratosulfate, sodium chondroitin sulfate A, sodium dermatan sulfate B, sodium chondroitin sulfate C, heparin, esterified chondroitin sulfate C, esterified heparin, and combinations thereof.
Claim 8
Independent Claim 108 words
A method for preparing a positively charged compound-containing matrix useful for delivery of a positively charged compound to a mammalian subject, comprising the steps of: providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups; forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking, wherein the second synthetic polymer is present in the mixture in molar excess compared to the second synthetic polymer; allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a negatively charged crosslinked synthetic polymer matrix; and reacting the matrix with the positively charged compound.
Claim 9
Independent Claim 108 words
A method for preparing a positively charged compound-containing matrix useful for delivery of a positively charged compound to a mammalian subject, comprising the steps of: providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups; forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking, wherein the second synthetic polymer is present in the mixture in molar excess compared to the second synthetic polymer; allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a negatively charged crosslinked synthetic polymer matrix; and reacting the matrix with the positively charged compound.
Claim 10
Dependent Claim 46 words
The method of claim 7 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
Claim 11
Dependent Claim 31 words
The method of claim 7 , wherein the first synthetic polymer is a polyethylene glycol, and wherein the nucleophilic groups are selected from a primary amino group and a thiol group.
Claim 12
Dependent Claim 23 words
The method of claim 7 , wherein the second synthetic polymer is a polyethylene glycol, and wherein the electrophilic groups are succinimidyl groups.
Claim 13
Dependent Claim 14 words
The method of claim 7 , wherein the positively charged compound is methylated collagen.
Claim 14
Dependent Claim 51 words
The method of claim 7 , wherein the positively charged compound is a glycosaminoglycan derivative selected from the group consisting of: esterified deacetylated hyaluronic acid, esterified deacetylated desulfated chondroitin sulfate A, esterified deacetylated desulfated chondroitin sulfate C, deacetylated desulfated keratan sulfate, deacetylated desulfated keratosulfate, esterified desulfated heparin, chitosan, and combinations thereof.

References Cited (Backward Citations)

US3619371A Cited
US3788948A Cited
US3742955A Cited
US3810473A Cited
US3876501A Cited
US4055635A Cited
US4179337A Cited
US3960830A Cited
US3949073A Cited
US4088538A Cited
US4101380A Cited
US4488911A Cited
US4002531A Cited
US4192021A Cited
US4261973A Cited
US4164559A Cited
US4238480A Cited
US4404970A Cited
US4390519A Cited
EP0013249B1 Cited
US4301144A Cited
US4279812A Cited
US4412947A Cited
US4320201A Cited
EP0042253B1 Cited
US4563490A Cited
US4314380A Cited
US4415665A Cited
US4414147A Cited
US4412989A Cited
US4451568A Cited
US4357274A Cited
US4415628A Cited
US4495285A Cited
US4495285B1 Cited
US4424208A Cited
US4582640A Cited
US4578067A Cited
US4704131A Cited
US4544516A Cited
US4737544A Cited
US4973493A Cited
US4592864A Cited
US4563351A Cited
US4515637A Cited
US4496689A Cited
EP0154447B1 Cited
US4703108A Cited
EP0157359A2 Cited
EP0171176B1 Cited
US4789663A Cited
US4678468A Cited
US4553974A Cited
US4687820A Cited
US4557764A Cited
US4563350A Cited
US4935465A Cited
US4689399A Cited
US4725671A Cited
US4655980A Cited
US4600533A Cited
US4732863A Cited
US4642117A Cited
US4795467A Cited
US4828563A Cited
US4670417A Cited
US4766106A Cited
US4851513A Cited
US4980403A Cited
US4774227A Cited
US4983580A Cited
EP0243179B1 Cited
US4745180A Cited
US4979959A Cited
US5364622A Cited
US4950699A Cited
US4847325A Cited
US5192316A Cited
EP0330389B1 Cited
US5024742A Cited
EP0341007B1 Cited
US5290552A Cited
US4950483A Cited
US5167960A Cited
US5264214A Cited
US5306500A Cited
US5162430A Cited
US5475052A Cited
US5510418A Cited
US5565519A Cited
US5328955A Cited
US5643464A Cited
US5324775A Cited
US5308889A Cited
US5292802A Cited
US5614587A Cited
US5304595A Cited
US5122614A Cited
US5612460A Cited
US5324844A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2004-11-26 2005-05-28 2005-11-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2008-11-26 2009-05-28 2009-11-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2012-11-26 2013-05-28 2013-11-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag